IPO - Profile


We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. We are developing our lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. COVID-19 has caused the current global pandemic that remains a significant global health crisis and has resulted in millions of deaths and lasting health problems in many survivors.

We believe that COVID-19 will become an endemic disease requiring a variety More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 18,200,000 Positive High 17.84%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • PricewaterhouseCoopers LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 05 Aug, 2021

Offer 06 Aug, 2021

Look Ahead

Lock Up Expiry Feb 06, 2022

IPO Terms

Offer Price $17.00
Offer Size 18M

Market Sentiments

Stock Price